S Fu
Overview
Explore the profile of S Fu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
357
Citations
2776
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nelson B, Naing A, Fu S, Sheth R, Murthy R, Piha-Paul S
Immunooncol Technol
. 2025 Feb;
25:101040.
PMID: 39981134
Immune checkpoint inhibitors (ICIs) have revolutionized oncology, yielding remarkable and durable responses in various cancers. However, a significant proportion of patients develop resistance to ICIs. The tumor microenvironment plays a...
2.
Fu S, Wu R, Liu C, Zhou Y, Lin Y, Wang J
Zhonghua Jie He He Hu Xi Za Zhi
. 2024 Oct;
47(10):978-983.
PMID: 39406547
Pulmonary hypertension is a disease that impairs cardiopulmonary function and is characterised by the limitation of progressive physical activity and decline in health-related quality of life. Patients usually present with...
3.
Xie P, Zeng Z, Li Z, Niu K, Xia T, Ma D, et al.
ESMO Open
. 2024 Oct;
9(10):103735.
PMID: 39368416
Background: Early-onset rectal cancer (EORC) is characterized by a unique disease process with different clinicopathological features compared with late-onset rectal cancer (LORC). Research on the risk of recurrence in EORC...
4.
Albiges L, Bourlon M, Chacon M, Cutuli H, Chuken Y, Zurawski B, et al.
Ann Oncol
. 2024 Sep;
36(1):99-107.
PMID: 39288844
Background: The evolving oncology treatment paradigm has created an unmet need for administration options that improve patient experiences and health care efficiencies. Patients And Methods: CheckMate 67T (NCT04810078) was a...
5.
Fu S, Yang Y, Wang C, Luo Q, Yu L
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi
. 2024 Jul;
36(3):279-285.
PMID: 38952314
Objective: To prepare and characterize the mouse polyclonal antibody against the dense granule protein 24 (GRA24) of , and explore its preliminary applications. Methods: The GRA24 coding sequences of different...
6.
Gouda M, Shunyakova J, Naing A, Dumbrava E, Hong D, Yuan Y, et al.
ESMO Open
. 2024 Jun;
9(6):103486.
PMID: 38914452
Background: Paclitaxel resistance limits durability of response in patients with initial clinical benefit. Overexpression of spleen tyrosine kinase (SYK) has been proposed as a possible resistance mechanism. This phase I...
7.
Huang W, Zhang L, Fu S, Shi G, Zeng H
Zhonghua Bing Li Xue Za Zhi
. 2024 Jan;
53(2):201-203.
PMID: 38281795
No abstract available.
8.
Tang Q, Zhou C, Zhang N, He Z, Fu S, Li X, et al.
Nan Fang Yi Ke Da Xue Xue Bao
. 2024 Jan;
43(12):2043-2052.
PMID: 38189390
Objective: To investigate the survival outcomes and risk factors for mortality in cirrhotic patients with probable spontaneous bacterial peritonitis (SBP). Methods: We retrospectively analyzed the clinical data of 323 cirrhotic...
9.
Wang Z, Bi H, Wang Y, Liu Q, Shao B, Li C, et al.
Actas Urol Esp (Engl Ed)
. 2023 Dec;
48(4):295-303.
PMID: 38160794
Objective: Tislelizumab, a monoclonal antibody against programed death protein-1 (PD-1), has shown encouraging antitumor activity in urothelial cancer. This study was designed to assess the efficacy and safety of tislelizumab...
10.
Feng L, Zheng Y, Liu Y, Zhao Y, Lei M, Li Z, et al.
J Nutr Health Aging
. 2023 Nov;
27(11):1012-1017.
PMID: 37997723
Background: Cognitive function has inevitable decline with advancing age in nature, and age-related cognitive decline (ARCD) is of increasing concern to aging population. Scarce study has involved the associations between...